Healthcare provider profile · identity verified

Mark R. Ellis, MD

Family Practice · SPRINGFIELD, MO · NPI 1982714804

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	379	104
Lisinopril	Lisinopril	262	76
Amlodipine Besylate	Amlodipine Besylate	226	69
Levothyroxine Sodium	Levothyroxine Sodium	226	62
Losartan Potassium	Losartan Potassium	207	63
Omeprazole	Omeprazole	171	45
Gabapentin	Gabapentin	159	45
Metformin Hcl	Metformin Hcl	156	32
Pantoprazole Sodium	Pantoprazole Sodium	153	40
Tamsulosin Hcl	Tamsulosin Hcl	138	41
Hydrochlorothiazide	Hydrochlorothiazide	135	32
Metformin Hcl Er	Metformin Hcl	127	34
Metoprolol Succinate	Metoprolol Succinate	126	39
Simvastatin	Simvastatin	125	34
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	118	28
Albuterol Sulfate Hfa	Albuterol Sulfate	108	27
Tizanidine Hcl	Tizanidine Hcl	105	28
Furosemide	Furosemide	102	30
Potassium Chloride	Potassium Chloride	98	27
Duloxetine Hcl	Duloxetine Hcl	96	23
Escitalopram Oxalate	Escitalopram Oxalate	95	20
Allopurinol	Allopurinol	93	23
Buspirone Hcl	Buspirone Hcl	92	19
Spironolactone	Spironolactone	89	23
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	85	24
Tramadol Hcl	Tramadol Hcl	85	18
Rosuvastatin Calcium	Rosuvastatin Calcium	80	25
Mirtazapine	Mirtazapine	79	21
Montelukast Sodium	Montelukast Sodium	78	20
Meloxicam	Meloxicam	74	22
Carvedilol	Carvedilol	71	19
Pravastatin Sodium	Pravastatin Sodium	69	18
Trazodone Hcl	Trazodone Hcl	69	17
Bupropion Xl	Bupropion Hcl	67	15
Lovastatin	Lovastatin	61	16
Fluticasone Propionate	Fluticasone Propionate	59	20
Sertraline Hcl	Sertraline Hcl	58	16
Prednisone	Prednisone	57	31
Famotidine	Famotidine	55	15
Eliquis	Apixaban	53	12
Metoprolol Tartrate	Metoprolol Tartrate	53	17
Xarelto	Rivaroxaban	47	suppressed
Alprazolam	Alprazolam	46	11
Fluoxetine Hcl	Fluoxetine Hcl	44	suppressed
Clonazepam	Clonazepam	39	suppressed
Synthroid	Levothyroxine Sodium	39	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	38	11
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	37	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	37	12
Citalopram Hbr	Citalopram Hydrobromide	32	suppressed
Finasteride	Finasteride	32	11
Azelastine Hcl	Azelastine Hcl	31	11
Spiriva Respimat	Tiotropium Bromide	31	suppressed
Baclofen	Baclofen	29	12
Warfarin Sodium	Warfarin Sodium	29	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	29	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	27	27
Dicyclomine Hcl	Dicyclomine Hcl	27	suppressed
Ezetimibe	Ezetimibe	27	11
Ozempic	Semaglutide	27	suppressed
Ropinirole Hcl	Ropinirole Hcl	27	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	26	suppressed
Pregabalin	Pregabalin	25	suppressed
Celecoxib	Celecoxib	24	suppressed
Alendronate Sodium	Alendronate Sodium	23	suppressed
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	22	suppressed
Glipizide Er	Glipizide	21	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Valsartan	Valsartan	21	suppressed
Donepezil Hcl	Donepezil Hcl	20	suppressed
Jardiance	Empagliflozin	20	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Mesalamine	Mesalamine	19	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	19	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	19	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	19	suppressed
Diazepam	Diazepam	18	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Lorazepam	Lorazepam	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Spiriva Handihaler	Tiotropium Bromide	17	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	16	16
Diltiazem 24hr Er	Diltiazem Hcl	16	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	12
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	16	14
Divalproex Sodium	Divalproex Sodium	15	suppressed
Doxepin Hcl	Doxepin Hcl	15	suppressed
Cholestyramine	Cholestyramine (With Sugar)	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Ramipril	Ramipril	14	suppressed
Temazepam	Temazepam	14	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	11
Premarin	Estrogens, Conjugated	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Azithromycin	Azithromycin	12	suppressed
Cholestyramine Light	Cholestyramine	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Atenolol	Atenolol	11	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	11	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	11
Fluconazole	Fluconazole	11	suppressed
Glipizide	Glipizide	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error